[go: up one dir, main page]

AR108277A2 - Péptidos inhibidores de fusión de hiv con propiedades biológicas mejoradas - Google Patents

Péptidos inhibidores de fusión de hiv con propiedades biológicas mejoradas

Info

Publication number
AR108277A2
AR108277A2 ARP170101125A ARP170101125A AR108277A2 AR 108277 A2 AR108277 A2 AR 108277A2 AR P170101125 A ARP170101125 A AR P170101125A AR P170101125 A ARP170101125 A AR P170101125A AR 108277 A2 AR108277 A2 AR 108277A2
Authority
AR
Argentina
Prior art keywords
seq
hiv fusion
biological properties
improved biological
inhibiting peptides
Prior art date
Application number
ARP170101125A
Other languages
English (en)
Original Assignee
Trimeris Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trimeris Inc filed Critical Trimeris Inc
Publication of AR108277A2 publication Critical patent/AR108277A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se provee un péptido inhibidor de fusión de HIV con una secuencia de aminoácidos de cualquiera de SEQ ID Nº 9, SEQ ID Nº 10, SEQ ID Nº 11, SEQ ID Nº 12, SEQ ID Nº 13, SEQ ID Nº 14, o SEQ ID Nº 15; y se provee una composición farmacéutica que comprende un péptido inhibidor de fusión de HIV y uno o más de un portador farmacéuticamente aceptable y portador macromolecular, y los usos y métodos de tratamiento provisto por estas composiciones.
ARP170101125A 2006-02-02 2017-05-02 Péptidos inhibidores de fusión de hiv con propiedades biológicas mejoradas AR108277A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76467406P 2006-02-02 2006-02-02

Publications (1)

Publication Number Publication Date
AR108277A2 true AR108277A2 (es) 2018-08-01

Family

ID=38437849

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP070100450A AR059300A1 (es) 2006-02-02 2007-02-02 Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas
ARP170101125A AR108277A2 (es) 2006-02-02 2017-05-02 Péptidos inhibidores de fusión de hiv con propiedades biológicas mejoradas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP070100450A AR059300A1 (es) 2006-02-02 2007-02-02 Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas

Country Status (15)

Country Link
US (3) US7456251B2 (es)
EP (1) EP1989220B1 (es)
JP (1) JP4682251B2 (es)
CN (1) CN101415723B (es)
AR (2) AR059300A1 (es)
AT (1) ATE537183T1 (es)
AU (1) AU2007218025A1 (es)
CA (1) CA2651793C (es)
CY (1) CY1113115T1 (es)
DK (1) DK1989220T3 (es)
ES (1) ES2381631T3 (es)
NZ (1) NZ570300A (es)
PT (1) PT1989220E (es)
TW (1) TWI341844B (es)
WO (1) WO2007097903A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4682251B2 (ja) 2006-02-02 2011-05-11 トリメリス，インコーポレーテッド 改善された生物学的特性を有するｈｉｖ融合阻害剤ペプチド
CA2700354A1 (en) * 2007-09-25 2009-04-02 Trimeris, Inc. Novel methods of synthesis for therapeutic antiviral peptides
AU2009260479A1 (en) * 2008-05-28 2009-12-23 New York Blood Center Bifunctional molecules for inhibiting HIV entry
CA2734081A1 (en) * 2008-08-13 2010-02-18 New York Blood Center Combination therapy of hiv fusion/entry inhibitors targeting gp41
CA2739288A1 (en) * 2008-10-16 2010-04-22 Shibo Jiang Immunoenhancer-linked oligomeric hiv vaccines
WO2010047826A2 (en) * 2008-10-24 2010-04-29 Trimeris, Inc. Dosing regimens and dosage formulations of an antiviral peptide therapeutic
CA2751865A1 (en) * 2009-02-09 2010-08-12 New York Blood Center, Inc. Trimeric hiv fusion inhibitors for treating or preventing hiv infection
CN102883740B (zh) 2010-05-03 2015-10-14 纽约血库公司 用于使hiv失活并阻断hiv的双功能分子
EP2794636A1 (en) * 2011-12-19 2014-10-29 Janssen R&D Ireland Hiv membrane fusion inhibitors
US20150045291A1 (en) 2012-04-04 2015-02-12 Yeda Research And Development Co., Ltd. Lipopeptide conjugates comprising sphingolipid and hiv gp41 derived peptides
CN103724404B (zh) * 2013-12-08 2016-11-02 北京工业大学 抑制hiv病毒与宿主细胞融合的非对映体多肽及其用途
GB201509782D0 (en) * 2015-06-05 2015-07-22 Isis Innovation Methods and products for fusion protein synthesis
CN109320593A (zh) * 2018-11-05 2019-02-12 中国人民解放军军事科学院军事医学研究院 抑制hiv感染的螺旋多肽及其用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016273A (en) 1975-07-16 1977-04-05 American Cyanamid Company Sustained release forms of certain oxazepines for parenteral administration
JPS55154991A (en) 1979-05-23 1980-12-02 Hisamitsu Pharmaceut Co Inc Beta-d-fructopyranoside derivative
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US5411951A (en) 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
US4629783A (en) 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
US5234520A (en) 1987-03-20 1993-08-10 Morgan Adhesives Co. Method of making an adhesive construction
CN1030256A (zh) * 1987-06-29 1989-01-11 日清食品株式会社 检测和治疗人类免疫缺陷病毒的方法和物质
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5462863A (en) 1989-02-09 1995-10-31 Development Center For Biotechnology Isolation of Hepatitis B surface antigen from transformed yeast cells
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
WO1993007603A1 (en) 1991-10-04 1993-04-15 Cornett Robert H Approaching emergency vehicle warning system
DE69326069T2 (de) 1992-07-20 2000-03-23 Duke University, Durham Zusammensetzungen die die hiv replikation inhibieren
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
DE69426292T2 (de) 1993-02-23 2001-05-17 Genentech, Inc. Stabilisierung von mit organischen lösungsmittel behandelten polypeptiden mit einem hilfsstoff
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
GB9404270D0 (en) 1994-03-05 1994-04-20 Delta Biotechnology Ltd Yeast strains and modified albumins
US6004549A (en) 1994-12-14 1999-12-21 Schering Corporation Crystalline protein controlled release compositions
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
JPH11507632A (ja) 1995-06-07 1999-07-06 トリメリス，インコーポレーテッド 併用療法を用いたｈｉｖおよび他のウイルス感染の治療
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
CN1173742C (zh) 1997-12-26 2004-11-03 山之内制药株式会社 缓释药物组合物
JPH11209456A (ja) * 1998-01-29 1999-08-03 Hitachi Chem Co Ltd 印刷配線板用難燃性エポキシ樹脂組成物及びこれを用いたプリプレグ、金属箔張り積層板
US6281331B1 (en) 1998-03-23 2001-08-28 Trimeris, Inc. Methods and compositions for peptide synthesis
US6258782B1 (en) 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6656906B1 (en) 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
DK1264840T3 (da) 1999-05-17 2009-11-16 Conjuchem Biotechnologies Inc Langtidsvirkende fusionspeptidinhibitorer af viral infektion
US6541020B1 (en) 1999-07-09 2003-04-01 Trimeris, Inc. Methods and compositions for administration of therapeutic reagents
US6992065B2 (en) 2000-04-19 2006-01-31 Genentech, Inc. Sustained release formulations
IL159048A0 (en) 2001-06-21 2004-05-12 Genentech Inc Sustained release formulation
CN1100564C (zh) 2001-08-29 2003-02-05 周根发 用于治疗hiv感染的药物、其组合物及其用途
US7045552B2 (en) 2002-09-27 2006-05-16 Trimeris, Inc. Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy
BRPI0418304A (pt) * 2004-01-07 2007-05-02 Trimeris Inc peptìdeo sintético, uso do mesmo, composição farmacêutica, seqüência de nucleotìdeos, e, métodos para inibição da transmissão de hiv para uma célula, para inibição da fusão de hiv, e para tratamento de um indivìduo infectado com hiv
JP2007529522A (ja) * 2004-03-15 2007-10-25 トリメリス，インコーポレーテッド ＨＩＶｇｐ４１由来ペプチドの部位特異的化学修飾
EP1725262B1 (en) 2004-03-15 2021-05-26 Nektar Therapeutics Polymer-based compositions and conjugates of hiv entry inhibitors
JP4682251B2 (ja) 2006-02-02 2011-05-11 トリメリス，インコーポレーテッド 改善された生物学的特性を有するｈｉｖ融合阻害剤ペプチド

Also Published As

Publication number Publication date
EP1989220A2 (en) 2008-11-12
WO2007097903A3 (en) 2008-05-22
US7456251B2 (en) 2008-11-25
PT1989220E (pt) 2012-03-23
DK1989220T3 (da) 2012-04-02
US20120040891A1 (en) 2012-02-16
TWI341844B (en) 2011-05-11
ATE537183T1 (de) 2011-12-15
AU2007218025A1 (en) 2007-08-30
US20090105143A1 (en) 2009-04-23
US8034899B2 (en) 2011-10-11
JP4682251B2 (ja) 2011-05-11
ES2381631T3 (es) 2012-05-30
CA2651793C (en) 2015-07-07
WO2007097903A2 (en) 2007-08-30
JP2009525051A (ja) 2009-07-09
CN101415723B (zh) 2014-06-25
AR059300A1 (es) 2008-03-26
CY1113115T1 (el) 2016-04-13
CA2651793A1 (en) 2007-08-30
EP1989220A4 (en) 2009-05-06
TW200806687A (en) 2008-02-01
NZ570300A (en) 2011-08-26
US20070179278A1 (en) 2007-08-02
CN101415723A (zh) 2009-04-22
EP1989220B1 (en) 2011-12-14

Similar Documents

Publication Publication Date Title
AR108277A2 (es) Péptidos inhibidores de fusión de hiv con propiedades biológicas mejoradas
ES2721172T3 (es) Una nueva clase de moléculas terapéuticas a base de proteínas
UY28250A1 (es) Composiciones farmacéuticas para inhibidores de la proteasa del virus de la hepatitis c
AR107020A2 (es) Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9)
AR036196A1 (es) Agentes de contraste multimericos dirigidos a base de peptidos
PT1548032E (pt) Péptidos kdr e vacinas que os contêm
ECSP10010413A (es) Inhibidores macrociclicos de serina proteasa
UY27650A1 (es) Composiciones farmacéuticas para inhibidores de proteasa viral de la hepatitis c
PE20161325A1 (es) L-asparaginasa tratada con peg
MY159958A (en) 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
ECSP034438A (es) Nuevos peptidos como inhibidores de ns-3-serina proteasa del virus de la hepatitis c
AU2003299519A1 (en) Hepatitis c virus inhibitors
AU2003248535A1 (en) Heterocyclicsulfonamide hepatitis c virus inhibitors
MX2009012609A (es) Composiciones y metodos para producir proteinas de fusion bioactivas.
WO2007008657A3 (en) Hepatitis c virus inhibitors
MX2010002018A (es) Peptido de cdh3 y agente medicinal que comprende al mismo.
RU2013126581A (ru) Мутанты стрептокиназы и их ковалентно модифицированные формы
ES2531115T3 (es) Combinaciones de clados de RrgB neumocócicos
AR030278A1 (es) Peptido modulador del receptor de trombopoyetina
EA200700976A1 (ru) Соединения в виде молекул-конъюгатов, обладающих повышенной активностью в отношении включения клеткой
WO2007029262A3 (en) Compositions and methods using same for the detection of viruses
AR065688A1 (es) Conjugados de peptidos antifusogenicos
AR047880A1 (es) COMBINACIoN DE UN INHIBIDOR DE RENINA Y DIURÉTICOS
HK1124075A (en) Hiv fusion inhibitor peptides with improved biological properties
BR0207476A (pt) Uso de um composto,e, composição farmacêutica

Legal Events

Date Code Title Description
FB Suspension of granting procedure